

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

DISCLOSEABLE TRANSACTION – DISPOSAL OF LISTED SECURITIES

THE DISPOSAL

On 6 August 2025, the Seller, an indirect wholly-owned subsidiary of the Company, disposed on the open market of an aggregate of 801,000 Jiangxi Rimag Shares at an aggregate consideration of approximately HK\$12.8 million (exclusive of transaction costs).

LISTING RULES IMPLICATIONS

As the highest applicable percentage ratio (as defined under the Listing Rules) in respect of the Disposal exceeds 5% but is less than 25%, the Disposal constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and are therefore subject to the notification and announcement requirements under the Listing Rules.

THE DISPOSAL

On 6 August 2025, the Seller, an indirect wholly-owned subsidiary of the Company, disposed on the open market of an aggregate of 801,000 Jiangxi Rimag Shares at an aggregate consideration of approximately HK\$12.8 million (exclusive of transaction costs). The average selling price (exclusive of transaction costs) for the Disposal of each Jiangxi Rimag Share is approximately HK\$15.94.

As the Disposal was made through the open market, the identities of the buyers of the Jiangxi Rimag Shares cannot be ascertained. To the best knowledge, information and belief of the Directors having made all reasonable enquiries, the buyers of the Jiangxi Rimag Shares and their respective ultimate beneficial owners are Independent Third Parties.

INFORMATION OF JIANGXI RIMAG

Jiangxi Rimag and its subsidiaries are a medical group specialised in medical imaging in the PRC, and are principally engaged in providing medical imaging services and solutions including imaging centre services, imaging solution services and Rimag Cloud services.

Set out below is a summary of certain audited consolidated financial information of Jiangxi Rimag for the two years ended 31 December 2024 as extracted from the annual results announcement of Jiangxi Rimag dated 28 March 2025:

	For the year ended 31 December 2024	For the year ended 31 December 2023
	<i>RMB'000</i>	<i>HK\$'000</i>
(Loss)/profit before income tax	(51,331)	43,381
(Loss)/profit for the year	(58,858)	36,574

Based on the annual result announcement of Jiangxi Rimag dated 28 March 2025, the audited net asset value of Jiangxi Rimag as at 31 December 2024 is approximately RMB1,484 million.

INFORMATION OF THE GROUP

The Group is principally engaged in the distribution and trading of pharmaceutical products and the provision of marketing and promotion services in the PRC.

REASONS FOR THE DISPOSAL

The Jiangxi Rimag Shares that have been sold by the Group under the Disposal were acquired by the Group as one of the cornerstone investors of Jiangxi Rimag when it launched its global offering of its H Shares in 2024. Please refer to the announcement of the Company dated 30 May 2024 published in this connection for details.

The Group considers that the Disposal represents an opportunity of the Group to realise the investment in Jiangxi Rimag and enhance the liquidity of the Group. The Group is expected to receive gross proceeds of approximately HK\$12.8 million in connection with the Disposal and recognise a gain of approximately HK\$0.8 million, being the difference between the consideration received from the Disposal and the aggregate costs (exclusive of transaction costs) of the relevant Jiangxi Rimag Shares. The Group intends to use such proceeds for general working capital.

As the Disposal was made at prevailing market prices and on the open market of the Stock Exchange, the Directors are of the view that the terms of the Disposal are fair and reasonable, on normal commercial terms and in the interests of the Company and its shareholders as a whole.

LISTING RULES IMPLICATIONS

As the highest applicable percentage ratio (as defined under the Listing Rules) in respect of the Disposal exceeds 5% but is less than 25%, the Disposal constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and are therefore subject to the notification and announcement requirements under the Listing Rules.

DEFINITIONS

Terms or expressions used in this announcement shall, unless the context otherwise requires, have the meanings ascribed to them below:

“Board”	the board of Directors
“Company”	New Ray Medicine International Holding Limited, a company incorporated in Bermuda with limited liability and the issued Shares of which are listed on Main Board (stock code: 6108)
“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“Director(s)”	the director(s) of the Company
“Disposal”	the disposal of a total of 801,000 Jiangxi Rimag Shares on the open market by the Group at a total cash consideration of approximately HK\$12.8 million (exclusive of transaction costs) on 6 August 2025
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC

“Independent Third Party(ies)”	party(ies) independent of the Company and the connected persons of the Company
“Jiangxi Rimag Share(s)”	the overseas listed foreign shares (each, a H Share) in the share capital of Jiangxi Rimag with nominal value of RMB1.00 each
“Jiangxi Rimag”	Jiangxi Rimag Group Co., Ltd. (江西一脈陽光集團股份有限公司), a joint stock company established in the PRC with limited liability and whose H shares are listed on the Main Board of the Stock Exchange (stock code: 2522)
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“PRC”	the People’s Republic of China, and for the purpose of this announcement, excludes Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“Seller”	China New Rich Medicine Holding Co. Limited (中國新銳醫藥控股有限公司), a company incorporated in Hong Kong with limited liability and a wholly-owned subsidiary of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“%”	per cent.

On behalf of the Board
New Ray Medicine International Holding Limited
Wang Qiuqin
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 6 August 2025

As at the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Chu Xueping and Ms. Zhou Wan; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.